Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Endocannabinoid system in food intake and metabolic regulation

Jesudason, David; Wittert, Gary

doi: 10.1097/MOL.0b013e328304b62b
Hyperlipidaemia and cardiovascular disease: Edited by Paul N. Durrington

Purpose of review As the incidence of obesity and the metabolic syndrome has increased, research has focused on the importance of the endocannabinoid system in the brain and peripheral tissues. Rimonabant, an inverse agonist of the CB1 receptor is being used therapeutically. This review presents recent advances in endocannabinoid physiology.

Recent findings The endocannabinoid system interacts with other anorexigenic and orexigenic pathways to regulate food intake in the hypothalamus, and the hedonistic value of food in the mesolimbic system. Endocannabinoid system overactivity contributes to hepatic steatosis, increased adipose tissue inflammation, dysregulated insulin signalling in the pancreas and disturbed oxidative pathways in skeletal muscle. The breakdown pathways for anandamide and 2-arachidonoylglycerol, the endocannabinoid receptor ligands, are reviewed, and the recent discoveries of endocannabinoid receptor polymorphisms and their relationship to obesity and metabolic disease noted. The favourable effect of rimonabant on fat mass glycaemic control, lipid metabolism and overall cardiovascular risk must be tempered by adverse effects on mood.

Summary The ubiquitous role of the endocannabinoid system in food intake and energy metabolism is now established. Drugs that manipulate different aspects of this system may benefit subjects with the metabolic and cachectic syndromes.

University of Adelaide, Adelaide, Australia

Correspondence to Gary Wittert, Professor of Medicine, Faculty of Health Sciences, University of Adelaide, North Terrace, Adelaide, Australia 5000, Australia Tel: +61 8 82225502; fax: +61 8 8223 3870; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.